233 related articles for article (PubMed ID: 16309423)
1. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
[TBL] [Abstract][Full Text] [Related]
2. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
[TBL] [Abstract][Full Text] [Related]
5. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.
De Vecchi E; Nicola L; Larosa M; Drago L
BMC Microbiol; 2008 Jan; 8():23. PubMed ID: 18230154
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.
Ling TK; Lee CC
Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
Wootton M; Bowker KE; Janowska A; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Oct; 44(4):445-53. PubMed ID: 10588304
[TBL] [Abstract][Full Text] [Related]
9. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
Credito KL; Lin G; Pankuch GA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Jan; 45(1):67-72. PubMed ID: 11120946
[TBL] [Abstract][Full Text] [Related]
11. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
[TBL] [Abstract][Full Text] [Related]
12. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Biedenbach DJ; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):349-53. PubMed ID: 9635909
[TBL] [Abstract][Full Text] [Related]
13. Microbiological profile of telithromycin, the first ketolide antimicrobial.
Felmingham D
Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.
Abbanat D; Webb G; Foleno B; Li Y; Macielag M; Montenegro D; Wira E; Bush K
Antimicrob Agents Chemother; 2005 Jan; 49(1):309-15. PubMed ID: 15616310
[TBL] [Abstract][Full Text] [Related]
15. Results from the Solithromycin International Surveillance Program (2014).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2016 Jun; 60(6):3662-8. PubMed ID: 27044551
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin.
Scaglione F; Demartini G; Dugnani S; Fraschini F
Chemotherapy; 2000; 46(5):342-52. PubMed ID: 10965100
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939
[TBL] [Abstract][Full Text] [Related]
18. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
[TBL] [Abstract][Full Text] [Related]
19. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.
Bogdanovich T; Bozdogan B; Appelbaum PC
Antimicrob Agents Chemother; 2006 Mar; 50(3):893-8. PubMed ID: 16495248
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis.
Schmitz FJ; Schwarz S; Milatovic D; Verhoef J; Fluit AC
J Antimicrob Chemother; 2002 Jul; 50(1):145-8. PubMed ID: 12096026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
